Trial Profile
Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms GINECO - NiQoLe; NiQoLe
- 06 Jun 2023 Results assessing safety and efficacy of niraparib maintenance in recurrent ovarian cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 22 Dec 2022 Status changed from active, no longer recruiting to completed.
- 25 Apr 2022 Planned End Date changed from 1 Apr 2023 to 1 Nov 2022.